Covance takes a $12.7M loss in Q2

Despite an uptick in revenue, Covance ($CVD) reported a $12.7 million loss in net income for the second quarter, as mounting restructuring costs put a damper on the company's earnings.

The Q2 slump has led Covance to scale back the high end of its 2012 earning projections by 10 cents, predicting to make between $2.50 and $2.70 per share.

The CRO announced cuts and closures for some of its facilities around the globe this quarter, resulting in asset impairment charges of $38.7 million on the quarter. The charge, combined with restructuring costs that more than doubled to $9.7 million, was enough to negate Covance's roughly $37 million revenue increase.

Driving the decline was Covance's flagging early-stage development unit, which saw its revenues decline by 5.2% in the quarter, a drop the company blames on shrinking demand for its toxicology and research products. The late-stage unit, on the other hand, reported a revenue boost of 12.8% thanks to Covance's clinical development business and central laboratories.

Despite the Q2 loss, analysts are optimistic about Covance's future earnings, Outsourcing-Pharma reports. Subtracting the one-time asset impairment charges, the hit in profits wasn't so bad, and the continued growth of the late-stage unit bodes well, analysts said.

- read Covance's release
- get Zachs.com's take
- read more from Outsourcing-Pharma

Suggested Articles

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.

Aetion has raised $50 million so far, and it plans to enhance its platform to support more complex therapeutic areas and expand its team.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.